Explore the words cloud of the RESHAPE project. It provides you a very rough idea of what is the project "RESHAPE" about.
The following table provides information about the project.
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
|Coordinator Country||Germany [DE]|
|Total cost||13˙137˙396 €|
|EC max contribution||13˙137˙396 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2022-12-31|
Take a look of project's partnership.
|1||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||coordinator||4˙137˙775.00|
|2||CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES||FR (NANTES)||participant||2˙023˙468.00|
|3||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||1˙998˙550.00|
|4||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||1˙548˙050.00|
|5||TISSUSE GMBH||DE (BERLIN)||participant||1˙026˙250.00|
|6||CELL THERAPY CATAPULT LIMITED||UK (LONDON)||participant||975˙625.00|
|8||NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN||DE (REUTLINGEN)||participant||499˙500.00|
|9||INNOVATION ACTA S.R.L.||IT (ROMA)||participant||426˙100.00|
Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy. Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments. Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation. Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESHAPE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESHAPE" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More